Straits Times Index
3,316.65 +8.75 (+0.26%) Nikkei
39,088.47 +471.37 (+1.22%) Hang Seng
18,930.02 -265.58 (-1.38%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,417.55 -424.59 (-0.61%) CMC Crypto 200
1,512.50 -13.92 (-0.91%)
Kymera Therapeutics, Inc. (KYMR)
After hours:
| Previous close | 35.32 |
| Open | 35.10 |
| Bid | 35.67 x 300 |
| Ask | 35.83 x 100 |
| Day's range | 34.36 - 36.24 |
| 52-week range | 9.60 - 45.31 |
| Volume | |
| Avg. volume | 586,329 |
| Market cap | 2.19B |
| Beta (5Y monthly) | 2.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.54 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.07 |
GlobeNewswireKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024,with Phase 1 data in the first half of 2025 WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinica
- GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual Meeting KT-333 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using
- GlobeNewswire
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; andTD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:
